Diagenic Exercises 10-for-1 Reverse Stock Split

Jun 03, 2011

NEW YORK (GenomeWeb News) – Diagenic recently announced a 10-for-1 reverse stock split, which took effect on May 30.

As a result of the split, each share of the company's stock was bumped up to NOK.50 ($.09) from NOK.05. After the split, the Norwegian firm had about 27 million shares of common stock outstanding.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Keep Them or Not?

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

Dunno Whose It Is

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

Knowing Risk From a Young Age

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

Science Translational Medicine Paper Finds Drug Combo Boosts KRAS Inhibitor Efficacy in Lung Cancer

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.

Featured White Papers

Optimized NGS Library Preparation with Acoustic Liquid Handling

Sep

25

Featured Webinar

Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers.

Oct

08

Featured Webinar

Integration of Single Cell and Spatially Resolved Methods for Understanding Neurodegeneration in ALS

This webinar will discuss a study that used spatial transcriptomics to gain insight into the molecular mechanisms of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu